Alamar Biosciences (ALMR)
Supplies NULISA assays and ARGO HT automation for protein-biomarker measurement.
Something off on this page? Send us feedback.
Sells automated precision-proteomics instruments, NULISA assays, consumables, and services to research and biopharma customers. Its model combines instrument placement with proprietary consumables and service activity.
Pairs NULISA assays with the automated ARGO HT benchtop system to measure protein biomarkers at very low concentrations in blood and other biological samples. The research-use-only platform serves research and academic institutions, biopharmaceutical companies, contract research organizations, and service laboratories.
The portfolio includes NULISAseq high-plex panels and NULISAqpcr single- or low-plex assays, with next-generation-sequencing or qPCR readouts for discovery and targeted applications. Its customer base extends internationally, and the business combines instrument placement, proprietary consumables, and services.
Commercial development depends on continued adoption of the ARGO/NULISA ecosystem by research and biopharma customers. The platform is designed for research use rather than clinical diagnostic use.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 11, 2026 | Stifel Nicolaus | Target | Target: $28 | Target: $32 |
| May 12, 2026 | Leerink Partners | Target | Target: — | Target: $35 |
| May 12, 2026 | Stifel Nicolaus | Target | Target: — | Target: $28 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $250.1M · Total debt $51.4M · Total assets $391.0M · Shareholders' equity $312.9M
- Revenue
- $29.4M
- Operating income
- −$13.5M
- Net income
- −$13.2M
No dividends on record.
| Institutions | 35.29% | 24.49M shares | |
|---|---|---|---|
| 87 holders · as of Jun 30, 2026 | |||
| Insiders | 29.47% | 20.45M shares | |
| 8 holders · as of Sep 16, 2026 | |||
| Strategic holders | 22.68% | 15.74M shares | |
| 1 holder · as of Aug 11, 2026 | |||
| Other | 12.56% | 8.71M shares | |
| remainder | |||
69.39M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Qiming Corporate GP VI, Ltd.1Strategic10 percent owner | 22.68% | 7.07M · 8.67M | filed Aug 11, 2026 |
Yuling Luo2Insiderdirector, officer: Chief Executive Officer | 9.21% | 4.53M · 1.86M | filed Aug 13, 2026 |
Nicholas NaclerioInsiderdirector | 9.18% | 6.37M | filed Apr 20, 2026 |
Nicholas NaclerioInsider | 9.17% | 6.36M | filed Apr 23, 2026 |
Sands Capital Ventures, LLCInstitution | 6.10% | 4.23M | as of Jun 30, 2026 |
- Qiming Corporate GP VI, Ltd.'s own ownership statement (13G, Aug 11, 2026) reports fewer shares than the transaction reports; the statement is used.
- Yuling Luo's transaction reports restate only vehicles that traded; the 2026 ownership statement (4.53M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 20, 2026 | Nicholas Naclerio | director | +235,294 | $17.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10 percent owner | +235,294 | $17.00 |
- Thermo Fisher Scientific
Olink for high-plex proteomic biomarker research
- Quanterix
Simoa for ultra-sensitive blood-biomarker measurement
- Illumina
SomaScan paired with Illumina NGS proteomics workflows
- Seer
Proteograph suite for deep, unbiased discovery proteomics
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alamar Biosciences | $33.02 | −0.60% | $2.30B | — | — | — | — |
| Thermo Fisher Scientific | $662.57 | +0.62% | $243.49B | 35.4 | 25.3 | 5.3 | +10.5% |
| Quanterix | $3.10 | −2.98% | $150.3M | — | — | 1.0 | +34.4% |
| Illumina | $251.92 | +1.80% | $37.44B | 46.2 | 44.2 | 8.3 | +9.4% |
| Seer | $1.87 | +0.54% | $102.3M | — | — | 7.4 | −23.4% |
| Median | 40.8 | 34.7 | 6.3 | +10.0% |